Evolva and Cornelius Group Bring New Fermented Resveratrol to Market

Resveratrol is an ingredient found in red grapes, blueberries, nuts and other plants. There is already a significant body of evidence showing that resveratrol can produce a positive impact on healthy-ageing variables like heart health, bone health, and blood-glucose control. Scientists have also found evidence in key biomarkers that resveratrol might slow the progression of Alzheimer’s disease and mimic the effects of a calorie-restricted diet. Evolva’s resveratrol comes from a fermentation process, producing a high-purity ingredient free of any environmental contaminants.

 

Joy Thomas, technical manager, Cornelius Group said: “Most resveratrol on the market today comes from the Japanese knotweed plant. Evolva’s resveratrol is different and is manufactured via the fermentation of yeast, making it a pure product that is free of pesticides and other impurities that can be found in knotweed extracts.”

 

The fermented resveratrol from Evolva has a purity over 98 per cent and is suitable for a broad range of products from capsules and tablets for dietary supplements to more complex applications in foods, animal nutrition and personal care products. Cornelius has a strong position in these application markets. As the exclusive distributor for Evolva’s fermented resveratrol, Cornelius will supply the ingredient to the UK, Republic of Ireland, Denmark, Norway, Sweden and Finland foods market, countries with a total population 96 million.

 

Ms Thomas added “Consumers are now demanding formulations derived from natural sources. The clean label trend is now seen more as a consumer expectation, as well as an industry standard. Fermentation of Evolva’s resveratrol is a natural process and supports the current market and consumer trends”.

 

Evolva CEO Neil Goldsmith, said: “Much of the resveratrol sold today is made from knotweed, which results in a lack of control over the standard of crop. The benefit of using the fermentation process is that it ensures the quality of the ingredient. Manufacturing resveratrol through the fermentation of yeast offers us, and our customers, peace of mind as it’s made from natural and sustainable feedstocks and has a stable, traceable and reliable supply chain.”

 

This distribution agreement does not change Evolva’s revenue guidance for 2016.

 

Earlier this year, Evolva announced that the European Patent Office granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived steviol glycosides. Evolva currently has 54 patents pending around the world related to yeast fermentation-derived steviol glycosides and they now have four commercially relevant stevia sweetener patents granted.